rolistobart

Generic: Rolistobart

rolistobart: 2 clinical trials tracked.

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.

BioSniper AIPage evidence connected

Prepared research question

What is verified about rolistobart, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

Clinical Trial Registry Records (2)

KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy

NCT04165096Registry updated 2026-06-26·Phase 2

Completed

Primary endpoint: Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

InterventionalRandomizedopen128 enrolledStarted 2020-01Completion 2025-0539 sites · Hungary, Israel, Italy, Poland…Merck Sharp & Dohme LLC

KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT04165070Registry updated 2026-08-25·Phase 1/Phase 2

Recruiting

Primary endpoint: Part A: Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

InterventionalRandomizedopen450 targetStarted 2019-12Completion 2032-1046 sites · Hungary, Israel, Italy, Poland…Merck Sharp & Dohme LLC

rolistobart evidence translation